Product Description
Mechanisms of Action: Sperm Degrader
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CONRAD
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: HIV Infections|Communicable Diseases|Acquired Immunodeficiency Syndrome|Deficiency Diseases
Phase 2: Vaginitis|Inflammation|Mucositis
Phase 1: HIV Infections|Contraception
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A13-126 | P1 |
Completed |
Contraception |
2016-03-01 |
|
Biomarkers | P2 |
Completed |
Vaginitis|Mucositis|Inflammation |
2013-04-01 |
|
HIVNET 008 | P1 |
Completed |
HIV Infections |
None |
|
HIVNET 016 Pilot | P3 |
Completed |
HIV Infections|Communicable Diseases|Acquired Immunodeficiency Syndrome|Deficiency Diseases |
None |